Biopharmaceutical News and Research

RSS

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere’s Convertible Promissory Note to May 26, 2010.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.

24 Feb 2010

Medical innovation: A real boon for American patients

An article in the Journal Miner recently highlighted the fact that many people are living longer, healthier and more productive lives thanks to medical innovation and research.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

Shire reports total revenues of $3,008 million for 2009

Shire plc the global specialty biopharmaceutical company, announces results for the year to December 31, 2009.

22 Feb 2010

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

An article that recently appeared in El Tejano Magazine highlighted the fact that many Americans are living longer, healthier and more productive lives because of medical innovation and research.

20 Feb 2010

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

A Stratton Spotlight article recently highlighted a Centers for Disease Control and Prevention (CDC) survey that showed a dramatic rise in the number of diabetes cases during the last 10 years and noted that pharmaceutical research and biotechnology companies are working on nearly 200 new medicines to treat this debilitating disease.

19 Feb 2010

NeoStem closes share public offering; expects $6.9 million in net proceeds

NeoStem, Inc. ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the closing of its previously announced 5,000,000 share public offering and the exercise of the over-allotment option in full by the underwriters for an additional 750,000 shares of the Company's common stock, bringing the total shares offered to 5,750,000.

19 Feb 2010

University of Missouri to offer health literacy courses for health professionals

The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.

19 Feb 2010

ARYx Therapeutics retains Cowen's services to optimize late-stage asset value

ARYx Therapeutics Inc., a biopharmaceutical company, today announced that it has retained Cowen and Company to explore strategic options for ARYx.

19 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

Epeius Biotechnologies (www.epeiusbiotech.com) announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in GMP, CMC, aseptic processing, and quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century.

18 Feb 2010

AltraVax acquires vaccine development technology package from Maxygen

AltraVax, Inc., a new, privately-held biopharmaceutical company, has acquired a vaccine development technology package from Maxygen, Inc. that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.

18 Feb 2010

Quintiles launches QTEA solution to speed patient recruitment

Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrolment at an individual site-level. Named Quintiles Trial Enrolment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of messaging and media outreach.

18 Feb 2010

Biopharmaceutical News and Research

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Novartis Pharma agrees to further extend maturity date of Emisphere Technologies' Convertible Promissory Note

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Shire receives FDA Fast Track designation for REPLAGAL

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Medical innovation: A real boon for American patients

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

Shire reports total revenues of $3,008 million for 2009

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

NeoStem closes share public offering; expects $6.9 million in net proceeds

University of Missouri to offer health literacy courses for health professionals

ARYx Therapeutics retains Cowen's services to optimize late-stage asset value

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

AltraVax acquires vaccine development technology package from Maxygen

Quintiles launches QTEA solution to speed patient recruitment

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News